Kornimate/medical-research-clean huggingface dataset:
tc99m macroaggregated albumin bronchial artery study

Conditions: Hemoptysis; Malignant Neoplasm; Lung Cancer

Summary: this is a single-arm, single-center, prospective pilot study to perform bronchial artery tc-99m-maa infusion to determine the predicted whole lung versus lung tumor dosimetry of a possible intra-arterial radioembolization.

this study is a prospective, single-arm pilot study for patients presenting with hemoptysis from lung cancers. prior to a therapeutic bronchial artery embolization (standard therapy), tc99m-maa will be administered to the bronchial artery and an imaging will be obtained to determine the distribution of maa. the primary objective will be quantification of tc99m-maa uptake within the tumor and surrounding structures (esophagus, bronchi, pericardium, spine). this is a purely descriptive study and no statistical comparison or correlation will be made. dosimetry will be reported for each patient, as well as range and mean with standard deviation. additional activity calculation methods and reporting metrics may additionally be used. non-statistical comparison will be made to literature-reported external-beam radiation dose-related tumor response and adjacent-organ toxicities to develop a preliminary assessment of the potential for efficacy and anticipated safety-profile of yittrium-90 bronchial artery radio-embolization.

Eligibility criteria:
inclusion criteria: * subjects 18 years of age and older * patients with known active lung cancer with a history of prior hemoptysis presenting for bronchial artery embolization will be considered. * patients must be presenting for secondary prophylaxis of hemoptysis * willing and able to understand and sign a written informed consent document. * willing and able to undergo all study procedures. exclusion criteria: * patients with current active hemoptysis * any acute or chronic inflammatory disease or medical conditions that in the investigator's opinion may interfere with the study procedures or the interpretation of the study results. * if female, not of childbearing potential or negative serum β-human chorionic gonadotropin pregnancy test prior to radiotracer injection. * if female, not nursing. * subjects who have exclusion criteria that would prevent them from receiving a ct scan or fluoroscopy, or administration of contrast. * history of allergic reactions attributed to compounds of similar chemical or biologic composition to macro-aggregated albumin

Keywords: lung cancer lung metastasis bronchial artery embolization maa study dosimetry
thalamic nuclei volumes in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the thalamus is composed of several nuclei interlocked in a complex anatomy. in multiple sclerosis (ms), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly mediated by csf. due to such pathophysiology and complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. we will test this hypothesis by using a new algorithm to automatically segment several nuclei that we will be applied to the french national ms database


Eligibility criteria:
inclusion criteria : * patient older than 18 years old. * with multiple sclerosis according to mc donald 2017 criteria or with clinically isolated syndrome and included with ofsep cohort. * phenotype known (rr, sp, pp or cis). * date of diagnosis known. * with at least one mri that includes 3d t1 and flair at 1.5t or 3t. exclusion criteria : * stroke * other causes of dementia not caused by multiple sclerosis (alzheimer's disease, parkinsonian syndromes...)

Keywords: multiple sclerosis thalamus nuclei atrophy
clinical, molecular and metabolic characteristics of parkinson's disease (pd) patients with parkin mutation

Conditions: Parkinson's Disease

Summary: parkinson's disease is a frequent neurodegenerative disorder. genetic forms of the disease have been recently identified. the monogenic form due to parkin mutation is responsible for many familial cases and sporadic forms. however, the relationship between the mutation and the genotype of patients is not fully established. the aim of this study is to compare clinical, metabolic and neuropsychological characteristics obtained in patients with parkin mutation with those of patients without parkin mutation.


Eligibility criteria:
inclusion criteria: * juvenile parkinson's disease (\< 45 years) * parkin mutation * normal brain magnetic resonance imaging (mri) exclusion criteria: * contraindication to brain mri * women without effective contraception

Keywords: parkinson's disease parkin mutation juvenile parkinson's disease positron emission tomography
multi institutional study in patient presenting with hematuria

Conditions: Bladder Cancer; Hematuria

Summary: the primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria.

the primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria. the secondary objective is to evaluate the predictive accuracy of a risk model including clinical factors such as age, gender, smoking history, and presence of gross versus microscopic hematuria compared to a model incorporating the same risk factors along with the methylation marker panel.

Eligibility criteria:
inclusion criteria: 1. subject is willing and able to give written informed consent 2. subject presents with or has a history of gross hematuria or microhematuria within the last 3 months exclusion criteria: 1. subject has an active urinary tract infection, current urinary retention, active stone disease (renal or bladder), current ureteral stents or nephrostomy tubes, prior bowel interposition, or recent genitourinary instrumentation (within 10 days) 2. subject has a current or past history of genitourinary or urologic cancer within 5 years 3. subject has an active (untreated) cancer of any type, except basal cell skin cancer within 5 years
mono versus polichemotherapy in non small cell lung cancer (nsclc) elderly patients

Conditions: NSCLC

Summary: between 10% and 25% of newly diagnosed stage iiib/stage iv patients currently receive single agent chemotherapy regimens. a significant proportion of these patients will be elderly (70 years of age) and many oncologists would consider intravenous vinorelbine or gemcitabine to be the standard of care in this patient population. it has been demonstrated that single agent vinorelbine offers therapeutic advantages to selected nsclc patients over best supportive care alone. carboplatin plus alimta have an acceptable toxicity profile and few clinical problems so it could be acceptable its use in elderly patients. a randomised study is being performed therefore to assess whether progression free survival, the primary efficacy endpoint for this study, achieved with carboplatin plus alimta is superior than achieved with gemcitabine, one of the current standards of care in elderly patients with advanced nsclc.


Eligibility criteria:
inclusion criteria: * nsclc, locally advanced (stage iiib) or metastatic (stage iv) disease, not amenable to curative surgery or radiotherapy * female or male patients aged 70 years and over * measurable disease according to recist criteria, with at least one measurable lesion * no prior chemotherapy, biological or immunological therapy * adeguate hepatic, renal and bone marrow function * ecog performance status ≤ 2 * life expectancy of at least 12 weeks exclusion criteria: * newly diagnosed cns metastases that have not been treated with surgery or radiation * less than 4 weeks since completion of prior radiotherapy or persistence of any radiotherapy related toxicity * any other experimental or anti-cancer therapy within 30 days before study drug administration * concurrent treatment with any other experimental or anti-cancer therapy
severe acquired brain injuries: prognostic factors and quality of care

Conditions: Brain Injuries, Acute

Summary: the main purpose of this project is to identify the medium-term prognostic factors for patients with severe acquired brain injuries and evaluate their impact. the secondary aim is to create a system of continuous assessment of the quality of care for each rehabilitation unit.

for each unit involved, it will be collected these data : * structural and organizational data of the rehabilitation units for severe acquired brain injuries; * detailed information on patients upon entering rehabilitation units for severe acquired brain injuries; * detailed information on patients, re-evaluated 4 months after the acute event statistical models will be implemented, in order to identify prognostic factors that could predict the probability to observe three events, which represent objectives of the rehabilitation process: decannulation, trunk control and total feeding by os. these events should be evaluated four months after the acute episode.

Eligibility criteria:
inclusion criteria: * patients with serious acquired brain injuries * admission to rehabilitation units exclusion criteria: - patients admitted more than 14 weeks after the acute event

Keywords: rehabilitation brain injuries
upper trapezius stretching in patients with cervical spondylosis

Conditions: Cervical Spondylosis

Summary: this study aims to investigate the effectiveness of upper trapezius stretching exercises on pain intensity, neck range of motion, and disability in patients with cervical spondylosis. patients with diagnosed cervical spondylosis will be randomly assigned to either a study group performing upper trapezius stretches or a control group. both groups will receive heat treatment and strengthening exercises. the study group will additionally perform specific upper trapezius stretching exercises. outcomes measures will be assessed before and after 4 weeks of intervention and will include neck pain intensity, range of motion, and disability using the neck disability index. the study hypothesizes that the study group will demonstrate greater improvements in pain, range of motion, and disability compared to the control group. the study findings could provide data to guide physical therapy management of cervical spondylosis.


Eligibility criteria:
inclusion criteria: * diagnosis of cervical spondylosis confirmed by orthopedic specialist * presence of neck pain for at least 3 months * willingness to participate in the study and comply with the intervention exclusion criteria: * recent neck trauma or fractures (within 6 months) * previous neck surgery * concurrent medical conditions that could affect neck pain and range of motion (e.g. rheumatoid arthritis) * concurrent physical therapy or rehabilitation for neck or shoulder * use of corticosteroids within past 3 months * pregnancy or serious circulatory conditions (due to use of heat pack) * known hypersensitivity to heat or cold * cognitive impairment that could interfere with ability to understand and complete self-report questionnaires and comply with interventions
cd5 car t-cell therapy for r/r t-cell lymphomas

Conditions: T-Cell Non-Hodgkin Lymphoma; T-cell Lymphoma (PTCL and CTCL)

Summary: this is a multi-center, open-label, non-randomized, single-arm clinical trial. refractory/relapse t-nhl patients are treated with autologous and allogeneic cd5 car t-cell therapy. the primary objective is to prospectively evaluate the safety of cd5 car t cell bridging to hsct in the treatment of r/r t-nhl. the primary endpoint is the type and incidence of dose limiting toxicity (dlt) within 21 days after cd5 car-t cell infusion. a total of 36 subjects is estimated to be enrolled.


Eligibility criteria:
inclusion criteria (patients who met all the inclusion criteria were eligible for enrolment): * relapsed or refractory cd7-positive t-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., hsct or chemotherapy); * male or female, age 14-70; * eastern cooperative oncology group (ecog) physical status score 0-2; * life expectancy is at least 60 days; * subjects should be capable of understanding and signing the informed consent form prior to any screening procedures. subjects are willing to follow the study visit schedule and associated study procedures as specified in the protocol. candidates between the ages of 19-70 years old will need to be sufficiently aware of and capable of signing the informed consent form; underage candidates between the ages of 14-18 years old will need to be sufficiently aware of the informed consent form and their legal guardian will also need to sign the informed consent form separately. exclusion criteria (patients who fulfil any of the following criteria may not be enrolled): * patients with history of allogeneic hsct but pbmnc is not available from prior- transplant donor for preparation of car t cells and peripheral blood tumour load \>30%; patients without history of allogeneic hsct and peripheral blood tumour load \>30%; * intracranial hypertension or cerebral impaired consciousness; * symptomatic heart failure or severe arrhythmia; * symptoms of severe respiratory failure; * with other types of malignancy; * diffuse intravascular coagulation; * serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value; * with sepsis or other uncontrollable infection; * suffering from uncontrollable diabetes mellitus; * severe mental disorders; * have significant intracranial lesions on cranial mri; * organ transplantation (excluding haematopoietic stem cell transplantation) history; * female patients (patients of childbearing potential) with positive blood hcg test; * hepatitis (including hepatitis b and c) and positive screening for aids and syphilis.
a study of mabthera (rituximab) in elderly patients with untreated follicular non-hodgkin's lymphoma (nhl)

Conditions: Non-Hodgkin's Lymphoma

Summary: this study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing mabthera, followed by either maintenance therapy with mabthera or no further therapy. the anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients 60-75 years of age; * b-cell follicular nhl; * no previous treatment; * active disease, with rapid progression. exclusion criteria: * other cancer within 3 years of study, except carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast treated with lumpectomy; * long-term use (\>1 month) of systemic corticosteroids; * central nervous system involvement; * history of significant cardiovascular disease; * positive test result for hiv, or hepatitis b or c.
safety and efficacy study of the effect of etanercept in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid arthritis. we are examining whether etanercept is effective in improving the nutritional status of hemodialysis patients as a consequence of its ability to decrease inflammation.

hemodialysis patients with end stage renal disease have a high mortality rate. in individual patients, mortality is associated with a low serum albumin concentration, a marker of poor nutritional status, and with elevated c-reactive protein, a marker of inflammation. since efforts to improve nutrition through dietary intake have not been successful, inflammation is thought to play a key role in determining nutritional status. recently, it has been shown that malnutrition, inflammation, and atherosclerosis are closely related in patients with chronic renal failure. it is our hypothesis that suppression of the cycle of inflammation, malnutrition, and vascular injury caused by atherosclerosis will improve survival in dialysis patients. this study is designed to examine whether suppression of the inflammatory response can be accomplished safely with etanercept and to determine if this suppression will improve nutritional status and clinical outcome in hemodialysis patients with poor nutritional status and evidence of inflammation.

Eligibility criteria:
inclusion criteria: * presence of end stage renal disease exclusion criteria: * history of tuberculosis history of recurrent infection recent ami, cancer within previous 5 years presence of hepatitis b, hepatitis c, hiv, systemic lupus erythematosis, presence of transcutaneous access (external catheter)

Keywords: etanercept malnutrition inflammation hemodialysis
adjuvant therapies for patients with hcc and mvi

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. though prognosis for patients with hcc is generally poor, hepatic resection can be an effective curative treatment, and its indications have been expanding in recent years. resection can be reasonably safe and effective even for patients with micro- or macrovascular invasion. however, the recurrence rate of hcc is as high as 74% for patients with intermediate and advanced hcc after resection. microvascular invasion is one of the main risk factors which influence risk of hcc recurrence and patient prognosis after resection. therefore, adjuvant therapy to prevent tumor recurrence after resection is so important to improve patient prognosis. nowadays, adjuvant transarterial chemoembolization (tace) is reported to be effective in reducing early recurrence rate and mortality for patients with hcc with risk factors of recurrence. sorafenib is a novel drug which is effective for advanced stage hcc. however, the efficacy of adjuvant sorafenib for postoperative hcc is unknown. therefore, it is interesting to investigate the efficacy of adjuvant sorafenib, and compare its efficacy to tace, tace plus sorafenib, or best supportive care for patients with postoperative hcc and microvascular invasion.


Eligibility criteria:
inclusion criteria: * age 18-75 years * diagnosis of hcc was confirmed by histopathological examination of surgical samples in all patients * patients with microvascular invasion by histopathological examination of surgical samples * patients have child-pugh a or b liver function * no previous neoadjuvant treatment * no evidence of macrovascular invasion, metastasis to the lymph nodes and/or distant metastases on the basis of preoperative imaging results and perioperative findings * no malignancy other than hcc for 5 years prior to the initial hcc treatment exclusion criteria: * history of cardiac disease * known history of human immunodeficiency virus (hiv) infection * known central nervous system tumors including metastatic brain disease * history of organ allograft * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study * pregnant or breast-feeding patients
emergency department healthcare education assessment and response for teen relationships: a pilot feasibility study

Conditions: Adolescent Behavior; Emergency Department; Abuse Physical; Abuse Mental; Abuse Verbal; Abuse Domestic; HEART; Intimate Partner Violence

Summary: this is a single-site, randomized, controlled trial. investigators will evaluate feasibility of the emergency department healthcare education assessment and response for teen relationships (ed-heart) intervention among adolescents age 14-19 years receiving care in the children's mercy emergency department.

this study is a mixed methods feasibility evaluation that will use a randomized controlled trial to assess feasibility of emergency department healthcare education assessment and response for teen relationships (ed-heart) (intervention arm: ed-heart + teen resource list; control arm: enhanced standard care \[standard care + teen resource list\]). adolescents age 14-19 years will be recruited and enrolled during an emergency department visit. investigators will evaluate feasibility using the eight bowen model feasibility constructs: acceptability, demand, implementation, practicality, adaptation, integration, expansion, and limited-efficacy testing. investigators will also examine theory of planned behavior constructs (attitudes, beliefs, perceived behavioral control, intention) to facilitate exploratory analysis of factors that may contribute to differential outcomes.

Eligibility criteria:
inclusion criteria: * emergency department (ed) patient 14-19 years of age. exclusion criteria: * developmental delay, severe illness, or cognitive impairment precluding informed consent/assent or completion of study activities, as determined by ed team or study team. * current ed evaluation for acute sexual assault/abuse. * current mental or behavioral health symptoms precluding completion of study activities, as determined by ed team or study team. * caregiver declines to step out to allow assent/consent in private or adolescent declines for caregiver to step out to allow assent/consent or participation in private. * adolescent is non-english speaking. * parent is non-english or non-spanish speaking.
a study of enfuvirtide (fuzeon) in patients with advanced human immunodeficiency virus-1 (hiv-1) infection

Conditions: HIV Infections

Summary: this study will evaluate the safety and tolerability of subcutaneous fuzeon in patients with advanced hiv-1 infection unable to construct an appropriate treatment regimen from currently available antiretroviral agents. the anticipated time on study treatment is 3-12 months, and the target sample size is 9 individuals.


Eligibility criteria:
inclusion criteria: * adult or adolescent patients greater than (\>)16 years of age * hiv-1 infection * cd4 count less than (\<)350/cubic millimeters (mm\^3) * hiv rna viral load \>10,000 copies per milliliter (copies/ml) while on highly active antiretroviral therapy (haart) * documented resistance, treatment-limiting toxicity, and/or \>=6 months' prior experience with each of 3 currently available classes of antiretroviral drugs. exclusion criteria: * women who are pregnant or breastfeeding; * patients unable to self-inject; * active, untreated opportunistic infection.
study comparing liquid and tablet buprenorphine formulations - 5

Conditions: Heroin Dependence

Summary: the purpose of this study is to compare liquid and tablet buprenorphine formulations.

participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. they each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.

Eligibility criteria:
inclusion criteria: m/f ages 21-50. opiate dependence according to dsm-iv criteria. currently enrolled in the outpatient protocol comparing liquid and tablet formulations of buprenorphine. agreeable to conditions of study and signed informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nursing women. dependence on etoh or benzodiazepines or other sedative-hypnotics. acute hepatitis. other medical conditions that deem participation to be unsafe.